TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota test… Read more
Market Cap & Net Worth: TCI GENE Inc. (6879)
TCI GENE Inc. (TWO:6879) has a market capitalization of $28.39 Million (NT$939.28 Million) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #31552 globally and #1865 in its home market, demonstrating a -0.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TCI GENE Inc.'s stock price NT$35.50 by its total outstanding shares 26458520 (26.46 Million).
TCI GENE Inc. Market Cap History: 2026 to 2026
TCI GENE Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $28.39 Million to $28.39 Million (0.00% CAGR).
TCI GENE Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TCI GENE Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6879 by Market Capitalization
Companies near TCI GENE Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to TCI GENE Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
TCI GENE Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, TCI GENE Inc.'s market cap moved from $28.39 Million to $ 28.39 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$28.39 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TCI GENE Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.39 Million USD |
| MoneyControl | $28.39 Million USD |
| MarketWatch | $28.39 Million USD |
| marketcap.company | $28.39 Million USD |
| Reuters | $28.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.